Visionary Holdings

GV

Market cap $1.13M

TORONTO, April 10, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”) today announced that it received a notification letter dated April 7, 2026 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

TORONTO, April 07, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (Nasdaq: GV) (the “Company”) today announced that it received a notification letter (the “Deficiency Letter”) from the Nasdaq Listing Qualifications Department on April 2, 2026, indicating that the Company is not in compliance with the continued listing requirements set forth in Nasdaq Listing Rule 5250(c)(1).

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”) today announced that it has entered into an Investment Cooperation Agreement with Qingdao Xihai Rongke Enterprise Operation Management Co., Ltd. in connection with a proposed US$20 million strategic investment for the Company's Qingdao anti-aging project in Qingdao West Coast New Area, China.

The collaboration is expected to support the Company's commercialization efforts through access to an established offline service network The collaboration is expected to support the Company's commercialization efforts through access to an established offline service network

HONG KONG, March 09, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise focused on biotechnology and healthcare, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), has signed a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex-President Super Injection, in cooperation with Huajin China Investment Company（”Huajin China”), alongside the Board-approved divestiture of its non-core business. These strategic actions mark the Company's formal transition into a commercialization acceleration phase within the high-end medical aesthetics sector.

Company Continues Expansion into North America and Europe as Part of Global Medical Aesthetics Strategy Company Continues Expansion into North America and Europe as Part of Global Medical Aesthetics Strategy

HONG KONG, March 02, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational and biotechnology and healthcare-focused company, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), today announced the signing of a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex---President Super Injection, in cooperation with Huajin China Investment Company（”Huajin China”), alongside the Board-approved divestiture of its non-core education business.

HONG KONG, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), continued execution progress under its previously signed commercial sales agreement with a total contract value of approximately US$9 million. The agreement, signed in September 2025, is currently in the implementation stage, with service activities underway.

HONG KONG, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (“GV” or the “Company”) (Nasdaq: GV), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has established three new regional wholly owned subsidiaries in Qingdao, Wuxi and Wuhu, China.

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”) announced today that in December 2025 it entered into a securities purchase agreement with an existing institutional investor (the “Investor”). In connection with the transaction, the Company issued to the Investor a senior secured convertible promissory note in the principal amount of $500,000 (the “December 2025 Note”) in exchange for gross proceeds of $450,000.